サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1790417

レッドバイオテクノロジーの市場規模、シェア、動向分析レポート：製品別、最終用途別、地域別、セグメント別予測、2025年～2030年

Red Biotechnology Market Size, Share & Trends Analysis Report By Product, By End Use (Academic Research Institutes, CMOs & CROs, Pharmaceutical & Biotechnology Companies, Others), By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 140 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.42円
レッドバイオテクノロジーの市場規模、シェア、動向分析レポート：製品別、最終用途別、地域別、セグメント別予測、2025年～2030年
出版日: 2025年07月03日
発行: Grand View Research
ページ情報: 英文 140 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

レッドバイオテクノロジー市場サマリー

レッドバイオテクノロジーの世界市場規模は2024年に5,465億9,000万米ドルと推計され、2025年から2030年にかけてCAGR 10.5%で成長し、2030年には9,977億4,000万米ドルに達すると予測されます。個別化医療への需要の高まり、バイオテクノロジー製品の調査への高額投資、遺伝子研究の進歩がこの分野を形成しています。

レッドバイオテクノロジーは、幹細胞、遺伝子治療、遺伝子工学、新薬やワクチンの開発などのバイオテクノロジー応用を扱う。レッドバイオテクノロジーとは、医療を改善し、病気と闘う身体を助けるために生物を利用するプロセスです。医療分野で使用される現代技術の一部です。人間の苦痛を和らげ、生活の質を向上させることができるため、製薬業界や医療分野で応用されています。生物学的医薬品を製造するために遺伝子工学の利用が増加していることは、主要な動向のひとつです。これには、治療用抗体のような特定のタンパク質を大量に生産できる遺伝子組み換え生物を作り出すための組み換えDNA技術の利用が含まれます。

同市場は、予測期間中に有利な成長を遂げると予想されています。急性の微生物感染症を治療する抗生物質から、AIDSの管理に役立っているアジドチミジンを含む抗HIV/AIDSのような慢性疾患まで、疾病管理において大きな進歩を遂げています。多くの製薬会社が、糖尿病やアルツハイマー病やパーキンソン病などの神経疾患に対するパイプライン製品を開発・製造しています。clinicaltrials.govによると、2021年1月現在、アルツハイマー病の治療薬として126の薬剤が臨床試験中であり、そのうち28の治療薬が第III相試験段階にあります。発酵技術はライフサイエンスやヘルスケア分野で広く使用されており、市場成長にプラスの影響を与えています。

同市場は現在も成長を続けており、医学の進歩を促進し、遺伝的要因に起因する疾患の特定を一変させる大きな可能性を秘めています。新しい検査は、疾患に関連する遺伝子のDNA配列の変化を検出することができ、早期発見は、早期治療によって疾患を回避したり、進行を遅らせたりする上で極めて重要な要素です。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 レッドバイオテクノロジー市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • レッドバイオテクノロジー市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析
  • レッドバイオテクノロジー市場：パイプライン分析

第4章 レッドバイオテクノロジー市場：製品の推定・動向分析

  • 製品セグメントダッシュボード
  • レッドバイオテクノロジー市場：製品変動分析
  • 世界のレッドバイオテクノロジー市場規模と動向分析（製品別、2018～2030年）
  • モノクローナル抗体
  • ポリクローナル抗体
  • 組み換えタンパク質
  • ワクチン
  • 細胞ベースの免疫療法製品
  • 遺伝子治療製品
  • 細胞治療製品
  • ティッシュ- エンジニアリング製品
  • 幹細胞
  • 細胞培養
  • ウイルスベクター
  • 酵素
  • キットと試薬
  • 動物モデル
  • 分子診断
  • その他

第5章 レッドバイオテクノロジー市場：最終用途の推定・動向分析

  • 最終用途セグメントダッシュボード
  • レッドバイオテクノロジー市場：最終用途変動分析
  • 世界のレッドバイオテクノロジー市場規模と動向分析（最終用途別、2018～2030年）
  • 学術調査機関
  • CMOとCRO
  • 製薬・バイオテクノロジー企業
  • その他

第6章 レッドバイオテクノロジー市場：地域の推定・動向分析

  • 地域市場ダッシュボード
  • 地域別市場シェア分析、2024年および2030年
  • 地域別レッドバイオテクノロジー市場：主なポイント
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • スウェーデン
    • デンマーク
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業/競合の分類
  • ベンダー情勢
    • Key company heat map analysis, 2024
  • 企業プロファイル
    • Merck KGaA
    • F. Hoffmann-La Roche Ltd
    • Pfizer Inc.
    • Regeneron Pharmaceuticals, Inc.
    • AstraZeneca
    • Takeda Pharmaceutical Company Limited
    • Gilead Sciences, Inc.
    • Biogen
    • Amgen Inc.
    • Celgene Corporation（acquired by Bristol-Myers Squibb Company）
図表

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global red biotechnology market, by region, 2018 - 2030 (USD Billion)
  • Table 3 Global red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 4 Global red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 5 North America red biotechnology market, by country, 2018 - 2030 (USD Billion)
  • Table 6 North America red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 7 North America red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 8 U.S. red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 9 U.S. red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 10 Canada red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 11 Canada red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 12 Mexico red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 13 Mexico red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 14 Europe red biotechnology market, by country, 2018 - 2030 (USD Billion)
  • Table 15 Europe red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 16 Europe red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 17 Germany red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 18 Germany red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 19 UK red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 20 UK red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 21 France red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 22 France red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 23 Italy red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 24 Italy red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 25 Spain red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 26 Spain red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 27 Denmark red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 28 Denmark red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 29 Sweden red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 30 Sweden red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 31 Norway red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 32 Norway red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 33 Asia Pacific red biotechnology market, by country, 2018 - 2030 (USD Billion)
  • Table 34 Asia Pacific red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 35 Asia Pacific red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 36 China red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 37 China red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 38 Japan red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 39 Japan red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 40 India red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 41 India red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 42 South Korea red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 43 South Korea red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 44 Australia red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 45 Australia red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 46 Thailand red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 47 Thailand red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 48 Latin America red biotechnology market, by country, 2018 - 2030 (USD Billion)
  • Table 49 Latin America red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 50 Latin America Academic research institutes market, by end use, 2018 - 2030 (USD Billion)
  • Table 51 Latin America red biotechnology market, by application, 2018 - 2030 (USD Billion)
  • Table 52 Brazil red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 53 Brazil red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 54 Argentina red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 55 Argentina red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 56 MEA red biotechnology market, by region, 2018 - 2030 (USD Billion)
  • Table 57 MEA red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 58 MEA red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 59 South Africa red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 60 South Africa red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 61 Saudi Arabia red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 62 Saudi Arabia red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 63 UAE red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 64 UAE red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 65 Kuwait red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 66 Kuwait red biotechnology market, by end use, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Red biotechnology market: market outlook
  • Fig. 10 Red biotechnology competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 Red biotechnology market driver impact
  • Fig. 16 Red biotechnology market restraint impact
  • Fig. 17 Red biotechnology market strategic initiatives analysis
  • Fig. 18 Red biotechnology market: product movement analysis
  • Fig. 19 Red biotechnology market: product outlook and key takeaways
  • Fig. 20 Monoclonal antibodies market estimates and forecast, 2018 - 2030
  • Fig. 21 Polyclonal antibodies market estimates and forecast, 2018 - 2030
  • Fig. 22 Recombinant proteins market estimates and forecast, 2018 - 2030
  • Fig. 23 Vaccines market estimates and forecast, 2018 - 2030
  • Fig. 24 Cell-based immunotherapy products market estimates and forecast, 2018 - 2030
  • Fig. 25 Gene therapy products market estimates and forecast, 2018 - 2030
  • Fig. 26 Cell therapy products market estimates and forecast, 2018 - 2030
  • Fig. 27 Tissue - engineered products market estimates and forecast, 2018 - 2030
  • Fig. 28 Stem cells market estimates and forecast, 2018 - 2030
  • Fig. 29 Cell culture market estimates and forecast, 2018 - 2030
  • Fig. 30 Viral vector market estimates and forecast, 2018 - 2030
  • Fig. 31 Enzymes market estimates and forecast, 2018 - 2030
  • Fig. 32 Kits and reagents therapy market estimates and forecast, 2018 - 2030
  • Fig. 33 Animal models market estimates and forecast, 2018 - 2030
  • Fig. 34 Molecular diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 35 Others market estimates and forecast, 2018 - 2030
  • Fig. 36 Red biotechnology market: end use movement analysis
  • Fig. 37 Red biotechnology market: end use outlook and key takeaways
  • Fig. 38 Academic research institutes market estimates and forecasts, 2018 - 2030
  • Fig. 39 CMOs & CROs market estimates and forecasts,2018 - 2030
  • Fig. 40 Pharmaceutical & biotechnology companies market estimates and forecasts,2018- 2030
  • Fig. 41 Others market estimates and forecasts,2018 - 2030
  • Fig. 42 Global red biotechnology market: regional movement analysis
  • Fig. 43 Global red biotechnology market: regional outlook and key takeaways
  • Fig. 44 North America market estimates and forecasts, 2018 - 2030
  • Fig. 45 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 46 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 47 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 48 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 49 UK market estimates and forecasts, 2018 - 2030
  • Fig. 50 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 51 France market estimates and forecasts, 2018 - 2030
  • Fig. 52 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 53 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 54 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 55 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 56 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 57 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 58 China market estimates and forecasts, 2018 - 2030
  • Fig. 59 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 60 India market estimates and forecasts, 2018 - 2030
  • Fig. 61 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 62 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 63 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 64 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 65 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 66 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 67 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 68 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 69 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 70 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 71 Kuwait market estimates and forecasts, 2018 - 2030
目次
Product Code: GVR-4-68040-042-9

Red Biotechnology Market Summary

The global red biotechnology market size was estimated at USD 546.59 billion in 2024, and is projected to reach USD 997.74 billion by 2030, growing at a CAGR of 10.5% from 2025 to 2030. The increasing demand for personalized medicine, high investment in the R&D of biotechnology products, and advances in genetic research are shaping the field.

Red biotechnology deals with biotechnological applications such as stem cells, gene therapy, genetic engineering, and the development of new drugs and vaccines. Red biotechnology is a process that uses organisms to improve health care and aid the body in fighting diseases. It is a subset of modern technology used in the field of medicine. It finds application in the pharmaceutical industry and the medical sector, as it helps alleviate human suffering and improves the quality of life. The increasing usage of genetic engineering to produce biological medicine is one of the major trends. This includes using recombinant DNA technology to create genetically modified organisms capable of producing large amounts of a specific protein, such as a therapeutic antibody.

The market is expected to witness lucrative growth during the forecast period. It has made significant advancements in disease control, from antibiotics for treating acute microbial infections to chronic conditions such as anti-HIV/AIDS, including azidothymidine, which has helped manage AIDS. Many pharmaceutical companies are developing and manufacturing pipeline products for diabetes and neurological disorders such as Alzheimer's and Parkinson's disease. According to clinicaltrials.gov, 126 agents were in clinical trials for the treatment of Alzheimer's disease as of January 2021, with 28 treatments in phase III trials. Fermentation technology is widely used in the life sciences and healthcare sectors, positively impacting market growth.

The market is still growing, with significant potential for driving medical advancements and transforming the identification of diseases caused by genetic factors. Novel tests can detect changes in the DNA sequence of genes linked to diseases, and early detection is a crucial factor in avoiding disease or slowing its progression through early treatment.

Global Red Biotechnology Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global red biotechnology market report based on product, end-use, and region:

  • Product Outlook (Revenue, USD Billion, 2018 - 2030)
  • Monoclonal Antibodies
  • Polyclonal Antibodies
  • Recombinant Proteins
  • Vaccines
  • Cell-Based Immunotherapy Products
  • Gene Therapy Products
  • Cell Therapy Products
  • Tissue-Engineered Products
  • Stem Cells
  • Cell Culture
  • Viral Vector
  • Enzymes
  • Kits and Reagents
  • Animal models
  • Molecular diagnostics
  • Others
  • End-User Outlook (Revenue, USD Billion, 2018 - 2030)
  • Academic Research Institutes
  • CMOs & CROs
  • Pharmaceutical & Biotechnology Companies
  • Others
  • Regional Outlook (Revenue, USD Billion, 2018 - 2030)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. End Use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. End use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Red Biotechnology Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Red Biotechnology Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
  • 3.4. Red Biotechnology Market: Pipeline Analysis

Chapter 4. Red Biotechnology Market: Product Estimates & Trend Analysis

  • 4.1. Product Segment Dashboard
  • 4.2. Red Biotechnology Market: Product Movement Analysis
  • 4.3. Global Red Biotechnology Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Billion)
  • 4.4. Monoclonal Antibodies
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.5. Polyclonal Antibodies
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.6. Recombinant Proteins
    • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.7. Vaccines
    • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.8. Cell-Based Immunotherapy Products
    • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.9. Gene Therapy Products
    • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.10. Cell Therapy Products
    • 4.10.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.11. Tissue - Engineered Products
    • 4.11.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.12. Stem Cells
    • 4.12.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.13. Cell Culture
    • 4.13.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.14. Viral Vector
    • 4.14.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.15. Enzymes
    • 4.15.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.16. Kits and Reagents
    • 4.16.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.17. Animal Models
    • 4.17.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.18. Molecular Diagnostics
    • 4.18.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.19. Others
    • 4.19.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Red Biotechnology Market: End Use Estimates & Trend Analysis

  • 5.1. End Use Segment Dashboard
  • 5.2. Red Biotechnology Market: End Use Movement Analysis
  • 5.3. Global Red Biotechnology Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Billion)
  • 5.4. Academic Research Institutes
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.5. CMOs & CROs
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.6. Pharmaceutical & Biotechnology Companies
    • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.7. Others
    • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. Red Biotechnology Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Dashboard
  • 6.2. Regional Market Share Analysis, 2024 & 2030
  • 6.3. Red Biotechnology Market by Region: Key Takeaways
  • 6.4. North America
    • 6.4.1. U.S.
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.2. Canada
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.3. Mexico
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5. Europe
    • 6.5.1. UK
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.2. Germany
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.3. France
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.4. Italy
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.5. Spain
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.6. Norway
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.7. Sweden
      • 6.5.7.1. Key country dynamics
      • 6.5.7.2. Regulatory framework/ reimbursement structure
      • 6.5.7.3. Competitive scenario
      • 6.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.8. Denmark
      • 6.5.8.1. Key country dynamics
      • 6.5.8.2. Regulatory framework/ reimbursement structure
      • 6.5.8.3. Competitive scenario
      • 6.5.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6. Asia Pacific
    • 6.6.1. Japan
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.2. China
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.3. India
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.4. Australia
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/ reimbursement structure
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.5. South Korea
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/ reimbursement structure
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.6. Thailand
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/ reimbursement structure
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7. Latin America
    • 6.7.1. Brazil
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.7.2. Argentina
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.8. MEA
    • 6.8.1. South Africa
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/ reimbursement structure
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.8.2. Saudi Arabia
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/ reimbursement structure
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.8.3. UAE
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework/ reimbursement structure
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.8.4. Kuwait
      • 6.8.4.1. Key country dynamics
      • 6.8.4.2. Regulatory framework/ reimbursement structure
      • 6.8.4.3. Competitive scenario
      • 6.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. Key company heat map analysis, 2024
  • 7.4. Company Profiles
    • 7.4.1. Merck KGaA
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. F. Hoffmann-La Roche Ltd
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Pfizer Inc.
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Regeneron Pharmaceuticals, Inc.
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. AstraZeneca
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Takeda Pharmaceutical Company Limited
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Gilead Sciences, Inc.
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Biogen
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Amgen Inc.
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. Celgene Corporation (acquired by Bristol-Myers Squibb Company)
      • 7.4.10.1. Company overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Product benchmarking
      • 7.4.10.4. Strategic initiativesa